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A B S T R A C T
Introduction: GM1 gangliosidosis is a rare autosomal recessive genetic disorder caused by the disruption of the
GLB1 gene that encodes β-galactosidase, a lysosomal hydrolase that removes β-linked galactose from the non-
reducing end of glycans. Deficiency of this catabolic enzyme leads to the lysosomal accumulation of GM1 and its
asialo derivative GA1 in β-galactosidase deficient patients and animal models. In addition to GM1 and GA1,
there are other glycoconjugates that contain β-linked galactose whose metabolites are substrates for β-ga-
lactosidase. For example, a number of N-linked glycan structures that have galactose at their non-reducing end
have been shown to accumulate in GM1 gangliosidosis patient tissues and biological fluids.
Objective: In this study, we attempt to fully characterize the broad array of GLB1 substrates that require GLB1 for
their lysosomal turnover.
Results: Using tandem mass spectrometry and glycan reductive isotope labeling with data-dependent mass
spectrometry, we have confirmed the accumulation of glycolipids (GM1 and GA1) and N-linked glycans with
terminal beta-linked galactose. We have also discovered a novel set of core 1 and 2 O-linked glycan metabolites,
many of which are part of structurally-related isobaric series that accumulate in disease. In the brain of GLB1
null mice, the levels of these glycan metabolites increased along with those of both GM1 and GA1 as a function of
age. In addition to brain tissue, we found elevated levels of both N-linked and O-linked glycan metabolites in a
number of peripheral tissues and in urine. Both brain and urine samples from human GM1 gangliosidosis pa-
tients exhibited large increases in steady state levels for the same glycan metabolites, demonstrating their
correlation with this disease in humans as well.
Conclusions: Our studies illustrate that GLB1 deficiency is not purely a ganglioside accumulation disorder, but
instead a broad oligosaccharidosis that include representatives of many β-linked galactose containing glycans
and glycoconjugates including glycolipids, N-linked glycans, and various O-linked glycans. Accounting for all β-
galactosidase substrates that accumulate when this enzyme is deficient increases our understanding of this se-
vere disorder by identifying metabolites that may drive certain aspects of the disease and may also serve as
informative disease biomarkers to fully evaluate the efficacy of future therapies.
1. Introduction
GM1 gangliosidosis is a Lysosomal Storage Disease (LSD) caused by
defects in the GLB1 gene which codes for β-galactosidase (EC 3.2.1.23),
a lysosomal hydrolase that cleaves β-linked galactose residues from the
non-reducing end (NRE) of glycan moieties found in various glyco-
conjugates. This rare autosomal recessive disease is characterized by
the large lysosomal accumulation in the brain of GM1 ganglioside and
its corresponding asialo derivative GA1, which are believed to cause
severe neurodegeneration with profound effects on morbidity and
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mortality in most patients [1,2]. GM1 gangliosidosis is typically clas-
sified in three forms (infantile, juvenile, and adult) which have disease
severities that are inversely proportional to residual enzyme activity.
The early infantile onset form is the most devastating form, resulting in
severe psychomotor retardation, hepatomegaly, splenomegaly and
skeletal abnormalities [2].
There are two known lysosomal beta-galactosidases, GLB1 and ga-
latosylceramidase (GALC), also known as galactocerebrosidase (EC
3.2.1.46). In the degradation of glycolipids, GALC appears to have a
strong preference for β-linked galactose conjugated proximally to lipids
such as in the case of galactosylceramide while GLB1 acts on β-linked
galactose distal to the lipid moiety as seen in GM1 and GA1 ganglio-
sides.
While commonly regarded as a gangliosidoses type LSD, β-ga-
lactosidase deficiency more accurately should be considered a broad
spectrum oligosaccharidoses since, in addition to glycolipids, a sub-
stantial number of soluble N-linked glycans also accumulate in GM1
gangliosidosis. These disease-related oligosaccharides were detected in
both affected tissues such as brain [3] and liver [4–6] as well as in
biological fluids such as urine [7–18] and amniotic fluid [17,19]. The
discovery of these additional storage metabolites is consistent with the
role of β-galactosidase in removing β-linked galactose from the NRE of
oligosaccharides moieties found not only in gangliosides but in other
glycoconjugates such as glycoproteins and keratan sulfate proteogly-
cans (Fig. 1).
Morquio B syndrome is another LSD that arises from mutations in
the GLB1 gene resulting in defects in β-galactosidase activity that pri-
marily effect the lysosomal degradation of keratan sulfate (KS) a gly-
cosaminoglycan polysaccharide enriched in cartilage and cornea and
made up of a repeat unit of galactose β-linked to N-acetylglucosamine-
6-sulfate (Fig. 1). Unlike GM1 gangliosidosis patients, Morquio B pa-
tients exhibit mostly a skeletal phenotype with symptoms that are lar-
gely non-neuropathic [2,20]. However, cases with a phenotype merging
GM1 gangliosidosis and Morquio B features have been described
[21,22]. The reasons for the differences in clinical outcome and meta-
bolite storage are not well understood but may stem from distinct
subsets of GLB1 mutations that preferentially impact different sub-
strates. The observation that different mutations in GLB1 result in dis-
tinct clinical outcomes and that β-galactosidase has numerous sub-
strates argues for a deep profiling of substrates that accumulate as a
result of β-galactosidase deficiency.
In this study we carried out a comprehensive survey of galacto-
side metabolite substrates of GLB1 that accumulate in a mouse model
and in human GM1 gangliosidosis patients. We performed substrate
analysis using glycan reductive isotope labeling liquid chromato-
graphy/mass spectrometry (GRIL LC/MS) [23,24] with data-dependent
tandem mass spectrometry in order to detect a wide range of GLB1
substrate metabolites that accumulate in the absence of enzyme ac-
tivity. We analyzed samples for glycolipids, gangliosides, N-linked and
O-linked glycan metabolites. A number of unique soluble glycan me-
tabolites, many of which are part of isobaric series composed of the
same number of hexose (Hex) and N-acetylhexosamine (HexNAc) re-
sidues were detected in affected tissues. While a number of these so-
luble oligosaccharides have been previously described and determined
to be predominantly N-linked glycan metabolites, we also detected a
number of abundant O-linked pentasaccharide (dp5) species consistent
with mucin-type O-linked glycans which have not been previously de-
scribed. These O-linked metabolites were detected in multiple tissues
and urine in GLB1 deficient mice as well as humans. None of these
soluble glycan metabolites were detected in either human or murine
unaffected control samples suggesting that they could make clinically
relevant disease-specific biomarkers that can be conveniently measured
in urine samples.
In addition to discovering new potential biomarkers, a better un-
derstanding of all of the β-galactosidase substrates that accumulate as a
result of enzyme deficiency and their associated pathological impacts
will broaden our understanding of the molecular and cellular me-
chanisms effected in this disease and may aid in evaluating efficacy of
future therapeutics.
2. Materials and methods
2.1. Materials
The A2G2 (NA2) N-glycan, 13C6-aniline, and sodium cyanoborohy-
dride (NaBH3CN), were purchased from (Sigma Aldrich, Milwaukee,
WI, USA). The endoglycosidase Endo S was purchased from New
England Biolabs (Ipswich, MA, USA). Hypersep Hypercarb PGC SPE
cartridges (25mg, 1mL) and Pierce BCA Protein Assay Kit were pur-
chased from ThermoFisher Scientific, Waltham, MA, USA). The Sep-
PAK C18 solid phase extraction (SPE) cartridges (100mg, 1mL) was
from Waters (Milford, MA, USA). All other chemicals were of reagent
grade or LC/MS grade for chromatography systems. Human re-
combinant β-Galactosidase was prepared as described [25].
2.2. Human brain and urine samples
All human brain tissues were obtained from the NIH NeuroBioBank.
The GM1 gangliosidosis sample was obtained from a female subject
who passed away at the age of 9.96 years. Her initial diagnosis by post-
mortem examination was inconclusive, but whole exome sequencing
identified two mutations in GLB1, c.765G > C (p.Gln255His) and
c.335A > C (p.His12Pro). Both mutations have previously been re-
ported in GM1 gangliosidosis patients, and the observed genotype
would be expected to lead to an age of death consistent with that ob-
served.
Human urine samples from subjects diagnosed with GM1 gang-
liosidosis were obtained from the Hospital de Clinicas de Porto Alegre,
Porto Alegre, Brazil.
All patient samples were collected and used for this study according
to a protocol approved by the Institutional Review Board (IRB) of each
submitting institution.
2.3. Gangliosides and BMP sample preparation
Brain samples were homogenized in water with 1.4 mm ceramic
beads using an Omni Bead Ruptor 24 Homogenizer (Omni
International, Kennesaw, GA, USA). Protein concentration of the
homogenate was determined using BCA assay. All homogenates were
diluted with water to 4 μg protein/μL homogenate. An amount of
sample equal to 200 μg of protein was extracted with 95/5 methanol/
glacial acetic acid (v/v). Samples were filtered through 10 kDa cen-
trifugal filter tubes and stored at −20 °C until use.
2.4. Glycolipidomics and glycosphingolipid acyl group characterization
LC/MS analysis was performed on an Acquity UPLC system
equipped with a HSS C18 column (1.8 μm, 1mm×150mm) (Waters,
Milford, MA, USA) connected to a Thermo LTQ Orbitrap XL mass
spectrometer. Solvent A was 74% methanol, 25% water, 1% formic acid
with 5mM ammonium formate and solvent B was 99% methanol, 1%
formic acid with 5mM ammonium formate. The initial composition was
80% A/20% B at a flow rate of 0.1 mL/min with the column tempera-
ture kept at 50 °C. Samples equal to 35 μg of protein were eluted using a
gradient method of 80% A/20% B isocratic for one minute, 80% A/20%
B to 0% A/100% B from 1min to 40min, 0% A/100% B isocratic to
55min, then re-equilibration at 80% A/20% B isocratic to 60min.
The LTQ Orbitrap XL was operated in the negative ion mode and the
sample introduced by ESI. The capillary temperature was set at 250 °C
with a spray voltage of 3 kV and capillary voltage of −4 V. The sheath
gas flow was set to 24 and the auxiliary gas flow to 3. Full scans were
performed at a resolution of 60,000 and a range of 300–2000m/z. Data-
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dependent collision induced dissociation (CID) was performed on the
three most intense ions within the full scan using a normalized collision
energy of 35 V and an activation time of 30ms. The CID profile was
used to detect glycolipids and specific acyl groups present in glyco-
sphingolipids.
2.5. Ganglioside and BMP analysis
Samples were analyzed for five different gangliosides (GM1, GM2,
GM3, GA1, GA2) and BMP (BMP 22:6) content with an Acquity UPLC
attached to a Xevo TQ-S micro Triple Quadrupole Mass Spectrometer
(Waters Corporation, Milford, MA).
For gangliosides, compounds were separated on an Acquity UPLC
Glycan BEH Amide column (Waters Corporation, Milford, MA). Solvent
A was 5mM ammonium acetate in 94.5% acetonitrile, 2.5% methanol,
2.5% water, and 0.5% formic acid. Solvent B was water. The initial
solvent composition was 95% A/ 5% B at a flow rate of 0.4 mL/min.
The column was kept at 50 °C. The LC elution gradient profile was hold
95% A/ 5% B for 2min, ramp to 50% A/ 50% B over 10min, hold at
50% A/ 50% B for 10min, then back to 95% A/5% B and hold for
4min. Samples were ionized by ESI in positive ion mode. The capillary
voltage was set at 1.0 kV, the desolvation temperature was set at 500 °C,
and the desolvation gas flow was 1000 L/h. Two precursor-product ion
transitions, one for the (d18:1/18:0) species, one for the (d18:1/20:0)
species, were monitored for each of the five gangliosides as follows:
GM1–1546.7 > 366.1, 1574.7 > 366.1; GA1–1255.7 > 366.1,
1283.8 > 366.1; GM2–1384.7 > 204.1, 1412.7 > 204.1;
GA2–1093.6 > 264.3, 1121.6 > 292.3; GM3–1181.5 > 264.3,
1209.6 > 292.3. The sum of the two transitions for each ganglioside
was used for quantitation. A standard reference curve containing all 5
gangliosides from 100 to 6.25 pg/μL was prepared with standards from
Enzo Life Sciences, Inc. (Farmingdale, NY) in 95/5 methanol/glacial
acetic acid (v/v).
For BMP phospholipid, compounds were separated with an Acquity
UPLC HSS C18 column (Waters Corporation, Milford, MA). Solvent A
was 5mM ammonium formate in 74% methanol, 25% water, and 1%
formic acid. Solvent B was 5mM ammonium formate in 99% methanol,
and 1% formic acid. The initial solvent composition was 80% A/ 20% B
Fig. 1. Catabolic pathways for glycolipid and glycoproteins effected by β-galactosidase. The substrate target for β-galactosidase is β-linked galactose residues situated
at the non-reducing end (NRE) of oligosaccharides found in many different glycoconjugates including glycolipids, glycosaminoglycans, and glycoproteins. Four
common types of glycoconjugate oligosaccharides containing galactose are shown with their branching structures along with a glycan symbol map used in this paper
(upper left). The catabolic pathways for GM1, Keratan Sulfate, N-linked glycans and O-linked glycans are shown (in boxes) along with the intermediate metabolite
structures (shown in the grey field enclosed by the dashed line) having β-linked galactose at the NRE which are likely substrates for β-galactosidase and thus putative
storage products that accumulate in β-galactosidase deficiency. For completeness, the catabolic pathway for sulfatides and galactosyl ceramide is included. The N-
glycan metabolite formed in the N-glycan catabolic pathway A2G2’ is also shown (blue font). Throughout this paper we use the Oxford notation scheme to refer to N-
glycans and related metabolites such as A2G2 and A2G2’.
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at a flow rate of 0.1mL/min. The column was kept at 50 °C. The LC
elution gradient profile was hold 80% A/ 20% B for 1min, ramp to 0%
A / 100% B over 5min, hold at 0% A/ 100% B for 10min, then back to
80% A/ 20% B and hold for 4min. Samples were ionized by ESI in
negative mode. The capillary voltage was set at 3.5 kV, the desolvation
temperature was set at 600 °C, and the desolvation gas flow was
1000 L/h. Two precursor-product ion transitions were monitored,
865.5 > 327.3 for BMP(22:6), and 665.4 > 227.2 for BMP(14:0). A
standard reference curve containing BMP(14:0) from 100 to 6.25 pg/μL
was prepared with a standard from Avanti Polar Lipids, Inc. (Alabaster,
AL). Because BMP(22:6) was not commercially available, BMP(22:6)
concentrations are reported as equivalents of BMP(14:0).
2.6. Biological sample preparation and glycan labeling
Tissues were homogenized, in water, with 1.4mm ceramic beads
using an Omni Bead Ruptor 24 Homogenizer (Omni International,
Kennesaw, GA, USA) and debris was removed by centrifugation at
14,000 rpm and 8 °C for 20min. The protein concentration of clarified
extracts was determined by BCA assay. An amount of sample equivalent
to 240 μg of protein, for tissues, or 100 μL, for urine, were diluted to
1mL with water and subjected to SPE purification using a Hypersep
Hypercarb PGE SPE cartridge following the manufacturer's instructions
and dried by centrifugal evaporation. The purified free glycans were
labeled with aniline by reductive amination as previously described
[23,24] (15 μL aniline, 15 μL 1M NaCNBH3 in 70:30 DMSO:HOAc) at
37 °C for 18–24 h. After labeling the remaining aniline was removed by
centrifugal evaporation at 37 °C. Samples were dissolved in water prior
to analysis.
2.7. Internal standard preparation
In order to generate the A2G2’ octasaccharide (dp8) standard, it was
necessary to first cleave off the reducing end GlCNAc residue from the
fully intact A2G2 (NA2) enneasaccharide (dp9). The A2G2 glycan
(2000 pmoles) was digested with Endo S (800 units) in a total volume of
20 μL of 50mM Sodium Phosphate pH 7.5 for 18–24 h followed by
purification on a Sep-PAK C18 SPE cartridge (100mg, 1mL), as to the
manufacturer's instructions, and dried by centrifugal evaporation. The
dried resulting A2G2’ glycan standard was then labeled with 13C6-ani-
line (15 μL, 15 μL 1M NaCNBH3 in 70:30 DMSO:HOAc) at 37 °C for
18–24 h and the remaining 13C6-aniline was removed by centrifugal
evaporation. Prior to analysis, the internal standard was dissolved in
water.
2.8. LC/MS analysis and quantitation of A2G2’
LC/MS analysis was performed on an Acquity UPLC system
equipped with a Glycan BEH Amide HILIC column (1.7 μm,
2.1 mm×150mm) (Waters, Milford, MA, USA) connected to a Thermo
LTQ Orbitrap XL mass spectrometer. Solvent A was 100mM
Ammonium Formate pH 4.5 and Solvent B was Acetonitrile with an
initial composition of 22% A/78% B and a flow rate of 0.2mL/min. The
column temperature was kept at 60 °C. Prior to injection an amount of
aniline labeled sample equal to 70 μg of protein, for tissues, or 20 μL, for
urine, was placed in a LC-MS sample vial along with 10 pmoles of 13C6-
aniline labeled A2G2’ biomarker internal standard and dried by cen-
trifugal evaporation. The samples were then dissolved in a solution of
22% A/78% B. The labeled free glycans were eluted using a gradient
profile of 22% A/78% B to 37% A/63% B over 65min, 100% A/0% B
for 6min, 100% A/0% B to 22% A/78% B in 5min and held there for
9min.
The LTQ Orbitrap XL was operated in the positive ion mode and the
sample introduced by ESI. The capillary temperature was set at 250 °C
with a spray voltage of 2 kV. The sheath gas flow was set to 58 and the
auxiliary gas flow to 9. Full scans were performed at a resolution of
60,000 and a range of 200–2250m/z. Data-dependent collision induced
dissociation (CID) was performed on the three most intense ions in the
full scan using a normalized collision energy of 35 V and an activation
time of 30ms. The N-glycan A2G2’ metabolite was determined by ratio-
metric comparison of the [12C6]aniline labeled endogenous A2G2’ ion
abundance with that of the known molar amount of the internal stan-
dard spike as previously described [23].
2.9. GRIL-LC/MS analysis of urinary keratan sulfate levels
Urinary glycosaminoglycan (GAG) polysaccharides were purified as
previously described for GAG isolations [23]. Briefly, GAG chains in
50 μL of urine were extracted by digestion with Pronase (Sigma-Al-
drich) at 37 °C for 24 h followed by anion-exchange chromatography
(DEAE-Sephacel, GE Healthcare Life Sciences, Marlborough, MA) and
subsequent desalting by size-exclusion chromatography (PD10 col-
umns, GE Healthcare Life Sciences, Marlborough, MA). After extraction,
urinary KS polysaccharide chains were subjected to enzymatic depo-
lymerization with keratinase II (Glycosyn Technologies, Lower Hutt,
New Zealand) which cleaves glycosidic linkages between GlcNAc6S and
either galactose or galactose 6-sulfate releasing both disaccharide and
larger oligosaccharide residues that can be subsequently analyzed by
GRIL-LC/MS [23]. Each sample was reconstituted in 50 μL 10mM so-
dium acetate and digested with 4mU of keratinase II for 16 h at 37 °C
before labeling with aniline as previously described [23]. While all of
the urinary KS samples were labeled with [12C6]aniline after depoly-
merization, an additional aliquot from one of the normal urine samples
(NHU4499) was also labeled with [13C6]aniline for use as a differen-
tially isotope-labeled internal reference standard. Equal amounts of this
internal reference standard were added to all of the [12C6]aniline la-
beled samples and analyzed by GRIL-LC/MS. Ion abundances for the
principal products from keratanase II digestion: g0A6, g6A6,
g0A6g0A6, and g0A6g6A6 (nomenclature previously described [26]) as
well as the fucosylated products g0A6(f0), g0A6g0A6(f0), g0A6(f0)
g0A6(f0), g6A6g6A6(f0), and Neu5Ac-g0A6g0A6(f0) were summed
together to give an aggregate ion intensity. The relative difference in
total urinary KS levels was determined ratiometrically by comparison to
the heavy isotope-labeled reference standard after normalization to
creatinine. For example, each sample's aggregate digestion product ion
intensity was divided by the corresponding aggregate digestion product
ion intensity for the reference standard. This ratio was then multiplied
by the ratio of creatinine levels in the sample and the internal reference
standard giving the relative difference in KS levels between the two.
2.10. Quantitative analysis of galactose from free glycans by high pH anion
exchange chromatography with pulsed amperometric detection (HPAEC-
PAD)
Free glycans from mouse brain samples (210 μg protein equivalent)
were dissolved in 20 μL of 50mM Sodium Acetate Buffer pH 4.5 and
incubated overnight with β-Galactosidase (4mU) at 37 °C to release
terminal galactose residues. Enzyme was removed from the samples
using a Sep-PAK C18 SPE cartridge (100mg, 1mL) as described above,
and the resulting flow thru and washes were brought to dryness by
centrifugal evaporation. Released galactose was analyzed by HPAEC-
PAD using a Dionex ICS-5000+ Ion Chromatography system equipped
with a pulsed amperometric detector (Thermo Fisher Scientific,
Waltham, MA, USA). Separation was performed using a CarboPac PA20
IC column (3× 150mm, Thermo) and guard (3×30mm, Thermo) at a
column temperature of 30 °C and a flow rate of 0.5 mL/min with an
injection volume of 100 μL. Monosaccharides in each sample (equiva-
lent to 80 μg protein) were separated isocratically in 12.5min with
10mM NaOH. Analytes were detected with a gold electrode, using the
following electric potentials: E1=+0.1 V for 0.4 s (integrating from
0.2 s to 0.4 s), E2=−2.0 V (0.02 s), E3=+0.6 V (0.01 s), and
E4=−0.1 V (0.06 s). The amount of galactose detected in each sample
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was calculated by comparing the sample galactose peak area to the
peak area of a known amount of galactose standard using Chromeleon
7.2 Chromatography Data System Software (Thermo) and normalized
to amount of protein.
3. Results
3.1. Liquid chromatography/mass spectrometry analysis of brain
homogenates from GLB1 null mice showed the disease-related accumulation
of ganglioside and phospholipid
As part of our comprehensive screen to identify unrecognized β-
galactosidase substrates that accumulate in GM1 gangliosidosis, we
performed lipidomics analysis on samples made by extracting brain
homogenates with acidic methanol to recover polar lipids including
glycolipids. We analyzed brain extracts from a 7-month-old normal
mouse and a 7-month-old GLB1−/− mouse [27] by performing reverse
phase LC/MS in the negative ion mode. Predominating ions were sub-
jected to data-dependent MS/MS product ion analysis using collision
induced dissociation (CID). We detected three peaks (number 1–3 in
Fig. 2) having significantly higher abundance in the GLB1 null mouse
compared to the age-matched normal control. Little or no signal was
detected for peak 3 in the normal control and thus it showed the
greatest fold increase. The m/z values and CID profile for these three
species correspond to Bis(monoacylglycero) phosphate (22:6) (BMP
(22:6)), GM1(d18:1/18:0), and GA1(d18:1/18:0), respectively. No
other accumulating lipid species extractable under the conditions used
were detected in the knockout mouse brain sample suggesting that
these are the only lipids showing large increases due to β-galactosidase
deficiency. The rest of the peaks detected in both GLB1 null and normal
mice have m/z values consistent with various phospholipids and only
BMP(22:6) exhibited significant accumulation in the knockout mouse
(Fig. 2). This phospholipid species is a negatively charged glycer-
ophospholipid enriched in endosomal/lysosomal membranes and
known to be a biomarker for phospholipidosis [28,29] and a storage
lipid that accumulates in GM1 gangliosidosis [30] thus, like GM1/GA1,
its elevation was expected. We did not detect increases in the steady
state levels for non-ganglioside glycolipids including lactosylceramide,
galactosyl ceramide, sulfatides, and monogalactosyldiacylglycerol re-
sulting from the disruption of the GLB1 gene. Thus, other than the
expected glyco- and phospho-lipids, we found no alternative lipid
containing disease-related biomarkers.
In order to further characterize the gangliosides accumulating in the
GLB1 null mouse brain, we determined the most abundant acyl-iso-
forms of GM1. We examined the product ion profile generated for the
most abundant ions during data-dependent collision induced dissocia-
tion (CID). Using this method, sialo glycolipids can be identified by the
neutral loss of 291 Da corresponding to Neu5Ac sialic acid. This ap-
proach revealed 12 different glycosphingolipids including lyso-GM1,
GM1 containing one of 8 different acyl groups, GM2, GM3 and GD1
(Supplemental Fig. 1). Most of these were obscured by the more
abundant phospholipids seen in Fig. 2 but were resolved by the data-
dependent CID. The steric acid containing GM1 ganglioside,
GM1(d18:1/18:0), was by far the most abundant isoform followed by
GM1(d18:1/20:0) together accounting for 93.8% (86.6% and 7.2%,
respectively) of the ion abundance attributable to GM1. Consequently,
these two species were chosen as the sole GM1 species to monitor using
LC/MS/MS for quantitative analysis. Furthermore, since GA1 is a pro-
duct of GM1 accumulation and both GM2 and GM3 are common in-
termediates to GM1 in the biosynthetic pathway, GA1, GM2, GA2, and
GM3 containing these two acyl chains were chosen as isoforms to
monitor for ganglioside profiling of brain samples.
We evaluated the ion abundance for all sialo ganglioside species in
the normal control sample and detected only GM1(d18:1/18:0) with a
smaller amount of GM1(d18:1/18:1) and GM2(d18:1/18:0) (data not
shown).
We developed a quantitative LC/MS/MS assay to analyze GM1/
GA1, GM2/GA2 and GM3 gangliosides with the two most abundant acyl
Fig. 2. LC/MS lipidomics screen of mouse brain homogenates for accumulating lipids and glycolipids in GLB1 null mouse brain. The lipidomics profile of acidic
methanol extracts made from water homogenates of whole brain from a 7-month-old normal mouse (top trace) and a 7-month-old Glb1−/− mouse (bottom trace)
were compared. The total ion current chromatograms (negative ion mode) for both samples are shown normalized to the same scale (relative abundance). Three
peaks numbered 1–3 corresponding to Bis(monoacylglycero) phosphate (22:6) (BMP(22:6), peak 1), GM1(d18:1/18:0) (peak 2), and GA1(d18:1/18:0) (peak 3) were
observed to be elevated in the GLB1 null sample compared to the normal control.
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chains discussed above and BMP(22:6) phospholipid in acidic methanol
extracts of brain homogenates. The results for a 7-month-old GLB1 null
female mouse (Fig. 3A) show a 14-fold increase in GM1 levels compared
to an age and gender-matched normal control. Since only a very small
amount of GA1 was observed in the wild type mouse we analyzed, the
increase in GA1 steady state levels observed in the affected mouse was
far greater, on the order of 486-fold. Comparing the levels of BMP
(22:6), we found a 15-fold increase in the affected brain sample over
that detected in the control (Fig. 3B). These results are consistent with
the genotype of this animal model [27].
3.2. Liquid chromatography/mass spectrometry analysis of brain
homogenates from GLB1 null mice showed the disease-related accumulation
of water soluble glycan metabolites
Consistent with the role played by β-galactosidase in the degrada-
tion of multiple glycans including those found in glycoproteins (Fig. 1),
a number of previous studies have shown the accumulation of free
glycan metabolites resulting from GLB1 deficiency. Many of these
earlier studies relied on thin layer chromatography (TLC), capillary
electrophoresis, or liquid chromatography to detect these species and
for subsequent biochemical analysis for structural characterization
[3–6,11,12,14,16,18]. Using these methods, most of these soluble gly-
cans were shown to be metabolites of N-linked glycans originating from
glycoproteins. More recently, mass spectrometry based methods have
been employed resulting in the discovery of even more of these types of
metabolites [7–10,13,15,17,19]. However, most of the MS studies uti-
lized direct sample introduction methods such as direct injection-ESI
and MALDI to detect these free glycans and consequently they were not
able to differentiate between isobaric species that may be present.
Furthermore, data-dependent tandem mass spectrometry, a very useful
means of characterizing and distinguishing between different isobars
based on their unique product ion profiles, could not be effectively used
without separation as part of the workflow. Consequently, the diversity
of these kinds of metabolites in GM1 gangliosidosis has likely been
under reported.
In order to gain further insights into the kinds of metabolites that
accumulate and may contribute to the progression of disease in GM1
gangliosidosis, we carried out a comprehensive analysis of glycan me-
tabolites. In order to account for a large number of isobaric species as
well as species with unique m/z values, we used forward phase amide-
column chromatography/mass spectrometry (FPAC-LC/MS). To gain
structural information, especially of multiple isobars, we used data-
dependent MS/MS with the ions of interest undergoing product ion
fragmentation by collision induced dissociation (CID). We analyzed
soluble glycans present in homogenized tissues or biological fluids such
as urine. The aqueous supernatant from these homogenates were clar-
ified by centrifugation and the glycans present in the supernatants were
end-labeled with aniline by reductive amination and subsequently
analyzed by Glycan Reductive Isotope Labeling LC/MS (GRIL-LC/MS)
as described in the Materials and Methods section. This method labels
the reducing end of oligosaccharides with aniline allowing the detec-
tion of reducing sugar species including incompletely degraded glycan
metabolites that accumulate in GM1 gangliosidosis. The aniline tag also
helps orient labeled molecules in the data-dependent MS/MS spectra by
relating the product ions to both the NRE and the reducing end of each
parent ion.
We first compared brain water homogenates made from 7-month-
old GLB1 null and normal control mice. In the affected sample we de-
tected a number of aniline-labeled species consistent with soluble
glycan metabolites (Fig. 4). Little or no trace of any of these glycan
metabolites was detected in the age-matched normal control mouse
brain consistent with these species being disease-related substrates for
β-galactosidase (Fig. 4, bottom trace). In the GLB1 null sample, we
observed oligosaccharides ranging in size from trisaccharides (dp3) to
dodecasaccharides (dp12) many of which were part of isobaric series
(Fig. 4 and Supplemental Fig. 2). The most abundant ion detected has
an m/z value (988.4) consistent with a pentasaccharide (dp5) composed
of three hexose (Hex) residues and two N-acetyl hexosamine (HexNAc)
residues (Hex3HexNAc2). A number of other dp5 isobaric species were
also observed. Data-dependent MS/MS analysis of the most abundant
ion detected two product ions formed by the neutral loss of either a
single Hex or HexNAc residue from the end opposite the aniline-tagged
reducing end. This suggests a biantennary parent ion with two distinct
NRE residues (Supplemental Fig. 3). These results are consistent with
the most abundant dp5 ion being a mucin-type O-linked glycan meta-
bolite which has not been previously described in the literature. The N-
linked dp5 glycan metabolite if present should have the sequence,
starting from the NRE, Gal-GlcNAc-Man-Man-GlcNAc (Supplemental
Fig. 4B, bottom panel). This N-glycan structure has only one NRE (β-
linked galactose) and will generate just one product ion after the neu-
tral loss of a monosaccharide from that end. On the other hand, Core 1
and Core 2 O-linked glycan metabolites can have two NRE residues
(Supplemental Fig. 3, Supplementary Fig. 4). This is especially true for
Core 2 species which have the base structure Gal-GalNAc-GlcNAc with
the reducing end being the bridging GalNAc. Careful examination of the
full product ion profile for this dp5 species gave consistent results with
either a Core 1 species with the general structure Gal-(GlcNAc)Gal-Gal-
GalNAc or a Core 2 species with the general structure Gal2-Gal-
(GlcNAc)GalNAc (Supplemental Fig. 3).
In total we detected nine isobars with m/z=988.4, seven of which
showed similar product ion profiles consistent with Core 1 and Core 2
Fig. 3. Ganglioside and BMP(22:6) profiling for
GLB1 null and age/gender-matched normal control
mouse brain extracts. The relative steady state levels
of gangliosides and BMP phospholipid were de-
termined for a brain sample taken from a GLB1−/−
mouse and an age and gender-matched (7-month-old
female) wildtype control. (A) Quantitative LC/MS/
MS ganglioside profiling showing the indicated
gangliosides as ng per μg protein of brain water
homogenate for both GLB1 null (GLB1−/−) and wild
type control (WT). The mean of three separate ana-
lyses are shown with error bars indicating standard
deviation. (B) Bis(monoacylglycero)phosphate
(22:6) levels expressed relative to a BMP (14:0/14:0)
internal standard for both GLB1 null and wild type
controls and expressed as ng BMP per μg protein. The
mean of three separate analyses are shown with error
bars indicating standard deviation.
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O-linked glycans and likely represent different branching variants. The
other two dp5 exhibit product ion profiles having just a single NRE and
are thus consistent with non-branched structures. These could be either
a linear extended O-linked Core 1 structure or the previously described
Gal-GlcNAc-Man-Man-GlcNAc dp5 species [8,15] (with the two man-
nose residues linked by either an α1–3 linkage or a α1–6 linkage, see
Fig. 1).
Besides the dp5 isobaric series, we also detected multiple
isobars for hexasaccharides dp6(Hex4HexNAc2), heptasaccharides
dp7(Hex4HexNAc3), and octasaccharides dp8(Hex5HexNAc3)
(Supplemental Fig. 2). However, many of the oligosaccharides larger
than dp5 had lower ion intensities which resulted in incomplete CID
spectra and consequently less structural information could be de-
termined from the product ions formed. A number of the dp6 and dp7
isobaric species did exhibit product ion spectra suggesting two different
NRE termini but the limited CID spectra for these larger oligosacchar-
ides is compatible with both N-linked and O-linked structures. Because
of the number of isobars for each oligosaccharide size class
(Supplemental Fig. 2): eight for dp6, eleven for dp7, and six for dp8, it
is likely that both N-glycans and O-glycans are present. The composi-
tion of the dp8 isobars (m/z=1515.5) is consistent with the previously
observed metabolite deriving from the complex N-linked glycan struc-
ture A2G2 (Oxford notation, see Fig. 1) which is a common glycan seen
in glycoproteins. For clarity, we used the prime symbol to distinguish
metabolites from the parent oligosaccharide from which they are de-
rived. For example, A2G2’ is the β-galactosidase substrate metabolite
that derives from A2G2 and differs from it by the loss of the first re-
ducing end GlcNAc (Fig. 1). Larger oligosaccharides with m/z values
consistent with metabolites for A3 and A4 glycans were also detected
but were assigned based only on m/z value and retention time without
benefit of CID data because of their low ion intensities (Fig. 4).
In order to gain more insight into the structure of these soluble
glycan metabolites, the soluble glycan fraction was subjected to enzy-
matic removal of non-reducing end galactose with recombinant β-ga-
lactosidase and the resulting remnant structures were analyzed by the
same method used to detect and characterize the glycan metabolites
Fig. 4. Soluble oligosaccharide metabolites in water homogenates from GLB1 null and wild type mouse brains. The soluble fraction from mouse brain homogenates
was end-labeled with aniline as described for the GRIL-LC/MS method in the Material and Methods section to detect reducing sugars. Labeled products were
separated by forward phase amide column chromatography and species with m/z values consistent with labeled oligosaccharides were detected by MS. The traces for
the GLB1 null brain sample and the corresponding normal control were normalized to 6×105 arbitrary ion intensity units for comparison. The degree of poly-
merization (number of monosaccharides in each oligosaccharide) is also shown (dp number) as well as putative oligosaccharide structures based on m/z values,
retention times, and available product ion profiles. The top panel shows the results from a 7-month-old GLB1−/−mouse brain with different oligosaccharides ranging
in size from pentasaccharides (dp5) to dodecasaccharides (dp12). Glycans that are putative metabolites deriving from mature A2G2, A3G3, and A4G4 N-linked
glycans are indicated using a prime symbol to the left (A2G2’, A3G3’, and A4G4’). Also shown is a series of pentasaccharides (dp5) with CID data consistent with O-
linked sugars that includes the most abundant glycan metabolite detected. The bottom panel shows the corresponding results for a 7-month-old normal mouse brain
control. The small peak (starred) in the chromatogram does not have an m/z value that corresponds to a glycan and is likely a contaminant.
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accumulating in the GLB1 null mouse brain. The resulting remnant
structures (Supplemental Fig. 4A) allowed us to restrict the pool of
possible structures for the soluble glycans accumulating in the knockout
mouse (Supplemental Fig. 4B).
From all of these results we were able to compile a table of the
oligosaccharide metabolites we detected in the GLB1−/− mouse brain,
including the total number of isobaric forms, and their putative struc-
tures (Table 1). A total of 56 distinct oligosaccharide structures based
on retention time, mass, and product ion profile were observed. In
addition to the oligosaccharide species labeled with aniline at their
reducing end, we detected a single species with m/z value= 1218.5
which appears to be a non-reducing oligosaccharide or an intact gly-
coconjugate since differential isotope labeling with both [13C6]Aniline
and [12C6]Aniline failed to produced differentially isotope-labeled
products. However, daughter ions consistent with the neutral loss of
two Hex and two HexNAc residues suggests this disease-related species
is or originates from a glycoconjugate (Table 1).
Thus, we have detected a diverse group of soluble glycan metabo-
lites in GLB1 deficient mouse brain including a number of Core 1 or
Core 2 mucin type O-linked glycans which have not been previously
described. One of these O-glycan metabolites, a pentasaccharide, is part
of an isobaric dp5 series and has the largest abundance of any of the
glycan metabolites detected in affected mouse brain suggesting that, if
like gangliosides, glycan metabolite accumulation drives certain aspects
of disease, it may play an important role in the progression of GM1
gangliosidosis.
3.3. Disease-related soluble glycan metabolites are detected in a number of
different tissues and biological fluids in β-galactosidase deficient mice
In order to determine if oligosaccharide metabolites similar to those
detected in brain also accumulate in other tissues in the GLB1 null
mouse, we screened for soluble glycans in liver, spleen, kidney, and
urine samples. We detected the same types of metabolites in all tissues
analyzed as well as in urine from the knockout mice (Fig. 5). Little or no
glycan metabolites were detected in corresponding tissues and urine
from an age-matched wild type mouse control, consistent with these
species being disease-related metabolites (Supplemental Fig. 5). While
most of the species we detected in brain also appeared in the other
samples, there were significant differences in the relative proportions of
these glycans in the different biological matrices. For example, the O-
linked pentasaccharide isobaric series (Hex3HexNAc2 – eluting between
Table 1
Glycan metabolites detected in GLB1 null mouse brain. The m/z values, monosaccharide composition, putative structures, likely type of glycoprotein linkage, and the
number of isoforms detected in a 7-month-old GLB1−/− mouse brain are shown. Insufficient ion recovery for the four largest oligosaccharide glycoforms resulted in
their assignment made by m/z value and retention time alone (star).
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20 and 24min) was detected in all samples tested. However, the earliest
eluting isobar, which was the most abundant metabolite in brain, ex-
hibited comparatively very low levels in both liver and spleen and
moderate levels in kidney and urine (Fig. 5). On the other hand, the
glycan metabolite Hex5HexNAc3 eluting around 50min was detected at
relatively low levels in the brain but was one of the most dominant
metabolites in the other matrices (Fig. 5). And finally, a dp7 species,
eluting at just over 37min, was one of the most dominant metabolites
in kidney but was detected at significantly lower levels in the other
matrices (Fig. 5). Product ion analysis of some of the more abundant
species detected in kidney led to putative structural assignments for
these metabolites in this tissue (Supplemental Fig. 6). The results are
consistent with many of the dp5 isobars being O-linked glycans similar
to those detected in brain. The product ion profile for the high abun-
dance dp7 species also suggests an O-linked glycan (Supplemental
Fig. 6E). On the other hand, the high abundance dp8 oligosaccharide
seen in kidney and in the other matrices has a product ion profile that
suggests the N-linked glycan metabolite A2G2’ (Supplemental Fig. 6F).
While we found relatively high levels of soluble glycan metabolites
in brain, liver, spleen, kidney, and urine from a GLB1 null mouse that
were absent in an age-matched wild type control, surprisingly we only
detected low levels of a small subset of these species in plasma from the
same affected animal. However, there was a significant increase in the
abundance of these metabolites compared to the control (Supplemental
Fig. 5). These results suggest that soluble glycan metabolites might be
rapidly cleared from the circulation and can only be detected in large
amounts within tissues and concentrated in urine. Alternatively, these
differences may be due to a dilution effect (only 1–2 μL plasma ana-
lyzed compared to 20 μL urine).
Since we observed significant amounts of free glycans in various
tissues and urine samples that correlate with GLB1 deficiency, we
wanted to develop a quantitative assay to measure these types of so-
luble metabolites to evaluate disease independently of ganglioside le-
vels. Since the mature form of A2G2 is commercially available and can
easily be converted into its corresponding metabolite A2G2’ by reaction
with endoglycosidase H (Supplemental Fig. 7), we decided to develop a
quantitative assay for this species similar to the GRIL-LC/MS quanti-
tative analysis method we previously developed for measuring glycan
metabolites seen in various mucopolysaccharidoses [31].
Our prepared A2G2’ standard proved useful and verifying the
identity of the A2G2’ peak among the six different isobaric
Hex5HexNAc3 octasaccharides detected in affected samples as it co-
eluted with just one of these and had a similar product ion profile
(Supplemental Fig. 7B). Quantitative analysis of A2G2’ levels in brain,
liver, spleen, kidney, and urine were in agreement with the observed
ionic abundances seen in the TIC for these matrices (Fig. 5). Compared
to the peripheral samples, brain samples exhibited the lowest steady
state levels of A2G2’ with< 20 pmole A2G2’/mg protein compared to
almost 1000 pmole A2G2’/mg protein in liver (Fig. 6). Interestingly,
while there was approximately a 40-fold increase in A2G2’ levels be-
tween wildtype and affected spleen, the wildtype levels in spleen were
higher than in all other matrices and were in fact similar to those seen
in affected brain (Fig. 6).
3.4. Both gangliosides and disease-related glycan metabolites increase with
age in GLB1 null mice but not in wildtype mice
Consistent with previously published results for this mouse model
[27], we observed increasing accumulation of ganglioside storage in the
brains of affected mice as they age (Fig. 7A). High levels of both GM1
and its corresponding asialo derivative, GA1, were detected at 1month
of age in GLB1 knockout mice compared to wild type controls which
showed only low levels of GM1 and no detectable GA1. At 4months of
age both GM1 and GA1 steady state levels were elevated compared to 1-
month-old GLB1 null mice. No significant difference in GM1 levels
between 1month and 4month mice was observed in normal controls.
Steady state levels for GM1 and GA1 increased further by 7months in
the knockout mouse while GM1 levels were not significantly changed in
the wild type mice. At none of the ages tested did normal control mice
exhibit significant levels of GA1 accumulation and only exhibited low
levels of GM1 (Fig. 7A). Comparing GM1 levels in the GLB1 null mice
and normal controls throughout the natural history study, GM1 levels
were approximately 9-fold higher in the knockout mice at 1month,
while at 7month the levels in affected mice were approximately 14
times higher.
Analogous to the progressive increases in ganglioside steady state
levels observed in GLB1 null mice as they age, brain levels of soluble
A2G2’ glycan also showed increases (Fig. 7B). However, unlike both
GM1 and GA1 gangliosides, which showed a steady increase, the A2G2’
levels didn't exhibit a significant change between 1 and 4months but
did show a significant increase between 4 and 7months of age. In all
cases, A2G2’ levels were below the limit of detection in age-matched
Fig. 5. Soluble free glycan metabolites in various tissue homogenates and urine
from a GLB1 null mouse. Soluble glycans were extracted from a 7-month-old β-
galactosidase deficient mouse and end labeled with aniline as described in the
Methods section. Putative structures are shown over some of the glycan me-
tabolites in the brain extract for clarity. The putative N-linked A2G2’ metabolite
is also indicated. Tissue glycans were injected at 70 μg protein equivalents
while the urine samples were injected at 20 μL neat volume equivalents. Ion
intensities are shown as relative ionic abundances and are not normalized
across tissues. Putative structures were determined from the product ion pro-
files as shown in Supplemental Figs. 3 and 6.
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Fig. 6. A2G2’ metabolite steady state levels in various tissues and urine from age-matched GLB1 null and normal wildtype control mice. A2G2’ steady state levels in
various tissue samples and in urine where compared between wild type and GLB1 null mice. Steady state A2G2’ levels are expressed as pmole A2G2’ per mg protein in
clarified tissue homogenate and urine. Numeric results are also shown in the table to the right.
Fig. 7. Natural history study of gangliosides and soluble oligosaccharide metabolites in the brain of GLB1 null and normal control mice. A. GM1 (blue bars) and GA1
(red bars) levels in brain homogenates from 1, 4 and 7-month-old GLB1 null and age-matched normal control mice. Values are normalized to μg protein equivalents
and are the mean of three animals for each time point, +/− SD. B. Corresponding A2G2’ brain levels in 1, 4, and 7-month-old null and normal control mice (n=3,
+/− SD). Values are normalized to μg protein equivalents. C. Corresponding total enzyme-released galactose in 1, 4, and 7-month-old GLB1 null and normal control
mice (n=3, +/− SD). Values are normalized to μg protein equivalents.
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wild type controls.
Despite observing increased steady state levels of both gangliosides
and glycan metabolites, we noticed that the amounts of gangliosides
accumulating in GLB1−/− mouse brain tissue far outpaced those of
A2G2’. For example, by 7months, we detected 25 ng of GM1 per μg
protein and only 0.037 ng A2G2’ per μg protein, almost a 700-fold
difference. However, comparing the relative abundance of A2G2’ in
GLB1 null mouse brain to the rest of the glycan metabolites observed
(Fig. 4) and seeing that A2G2’ is far less abundant in brain compared to
other tissues (Fig. 5), A2G2’ levels vastly underestimate the accumu-
lation of free glycans in the brains of knockout mice.
In order to more faithfully compare the amount of gangliosides and
glycan metabolites that accumulate in disease, we measured the total
amount of non-reducing end β-linked galactose present in the aqueous
fraction of brain homogenates from affected and wildtype mice at 1, 4,
and 7months of age. Soluble glycans purified from these samples were
treated with recombinant β-galactosidase enzyme and the released
galactose quantified using ion chromatography and pulsed ampero-
metric detection (PAD) (Supplemental Fig. 8). The observed pattern of
increasing enzymatically-released galactose accumulation with age was
very similar to that of A2G2’ alone, thus justifying its use as a surrogate
for total disease-related glycan metabolites (Fig. 7B and C). In normal
control mice, where A2G2’ levels were below the limit of detection,
galactose levels were detectable at relatively low levels after β-ga-
lactosidase treatment. Galactose levels were far higher in all of the af-
fected samples tested.
Comparing the total amount of gangliosides with the total amount
of liberated galactose can be useful since much of this galactose is from
the non-reducing ends of glycan metabolites. Therefore, these galactose
levels are a good stoichiometric estimate of these metabolites when
internal standards such as the one used for A2G2’ are not available. For
example, at 7months of age, approximately 3.7 ng galactose/μg protein
was detected in GLB1 null mouse brains (Fig. 7C). If we assume that
most of the glycan metabolites are dp5 and have two NREs per glycan
as suggested by our product ion analysis results, then with the mole-
cular weight of galactose being 180 Da, approximately 0.01 nmoles of
dp5 were detected. The molecular mass of dp5 is 910 Da which equates
to 9.1 ng glycan metabolite per μg protein detected. Comparing this to
approximately 26 ng of GM1 in the same samples, the estimated glycan
levels are significant. In other tissues where ganglioside accumulation is
negligible, glycan accumulation may be very important for disease
progression involving those tissues. Finally, since gangliosides are not
normally detected in an important non-invasive sample matrix such as
urine but glycan metabolites are, we decided to use free glycan analysis
as our primary biomarker assay for this disease.
3.5. Both gangliosides and disease-related glycan metabolites are elevated in
GLB1 deficient human brain tissue and urine suggesting similar patterns of β-
galactosidase substrate accumulation in both affected mice and humans
After observing a variety of glycan metabolites including what ap-
pear to be newly discovered O-glycans accumulating in GLB1 null mice,
we wanted to investigate if a similar constellation of N-glycan and O-
glycan metabolites also accumulate in human GM1 gangliosidosis pa-
tients.
We obtained post mortem brain samples (cerebral cortex) collected
from an affected patient and two normal controls and subjected these to
glycolipid analysis. RNA sequencing indicated that the affected human
had mutations c.765G > C (p.Gln255His) and c.335A > C
(p.His112Pro) in the GLB1 gene locus. In comparing the relative
abundance of GM1 acyl-isoforms present in the human samples, we
found the same pattern we observed in mice with GM1(d18:1/18:0) and
GM1(d18:1/20:0) contributing to most of the ganglioside ion intensity.
We carried out ganglioside and BMP phospholipid profiling as we did
before with murine samples. As expected, we found both GM1 and the
corresponding asialo derivative, GA1, as well as BMP-phospholipid
were elevated in the human GM1 gangliosidosis brain sample compared
to the normal brain samples (Fig. 8).
We next carried out soluble glycan analysis of water homogenates
made from these human brain samples. Consistent with our results in
mouse brain tissues (Fig. 4), we found similar types of glycan meta-
bolites in the human GM1 gangliosidosis patient brain but not in the
unaffected controls (Fig. 9) including a number of isobaric penta-
saccharides (m/z=988.4). Many of these dp5 species gave CID product
ion spectra consistent with metabolites derived from mucin type ex-
tended Core 1 or 2 O-linked glycans (Supplemental Fig. 9). Interest-
ingly, the most dominant dp5 isoforms in the human patient did not
coincide with the most dominant isoform detected in mouse brain
(compare Fig. 4 with Fig. 9) which may be due to species differences.
In addition to the dp5 isobaric series, various larger glycan meta-
bolites were also detected including multiple dp6 (m/z=1150.4), dp7
(m/z=1353.5), and dp8 (m/z=1515.5) oligosaccharides. For many
of these larger glycan isoforms, structural evaluation using CID failed to
determine if they derived from either N- or O-linked glycans. An ex-
ception was A2G2’ which was structurally identified by having the
same retention time and similar product ion spectra as that of the A2G2’
internal standard. Larger oligosaccharides (dp9 and dp10) were in-
ferred to be metabolites derived from A3G2 and A3G3, based on their
m/z values and retention times (the two putative structures shown to
the right of A2G2’ in the top panel of Fig. 9A).
Quantitative analysis of A2G2’ steady state levels in both affected
and unaffected brain samples showed A2G2’ levels to be below the
lower limit of detection in the unaffected controls. However, in the
GM1 gangliosidosis patient, we observed A2G2’ levels to be largely
elevated in comparison (Fig. 9B). However, as we observed in GLB1 null
mice, increases in GM1 and GA1 ganglioside levels outpaced those of
A2G2’ (24.2 ng GM1/μg protein and 1.01 ng A2G2’/μg protein). Re-
gardless, given the number of distinct glycan metabolites detected,
when compared as a class to gangliosides, soluble glycans likely re-
present a large proportion of GLB1 substrates that accumulate as a re-
sult of GM1 gangliosidosis. This is exactly what we determined above
for the mouse model by measuring the amount of β-linked terminal
galactose present in samples (Supplemental Fig. 8).
We next looked for the presence of soluble glycans in urine samples
collected from six pediatric GM1 gangliosidosis patients (Table 2) and
six unaffected normal pediatric controls. In all of the GM1 gang-
liosidosis patients we found glycan metabolites similar to those we
detected in both the GM1 gangliosidosis patient brain and the mouse
model. As expected, little or no soluble glycans were detected in any of
the normal controls (Fig. 10A). In the disease samples, we observed a
series of dp5 oligosaccharide isobars similar to the O-glycan penta-
saccharides observed in both human and mouse samples as well as
comparatively high levels of larger oligosaccharides including A2G2’.
We next quantified A2G2’ in these urine samples and compared the
results after normalizing to creatinine levels. Urinary A2G2’ levels in all
of the affected patients were greatly elevated compared to the normal
controls, which were at or below the limit of detection (Fig. 10B). In-
terestingly, a patient (P12–2363) with the mutation R59H, a GLB1
mutation commonly found in Brazil [32,33], where all the affected
urine samples were sourced, had the highest urinary A2G2’ levels. This
patient also exhibited significant clinical symptoms at birth (Table 2)
suggesting a possible correlation between severity and biomarker le-
vels. This observation will need to be tested in a much larger set of
patient samples.
Genetic mutations effecting the GLB1 gene can result in two clini-
cally different diseases, GM1 gangliosidosis and Morquio B [2,20,34].
With the former having a neurodegenerative phenotype and char-
acterized by increases in gangliosides while the latter exhibits a skeletal
phenotype and is associated with increases in keratan sulfate (KS).
Since significant levels of KS can be measured in normal urine, we
wanted to determine if urinary KS levels are elevated in any of the six
GM1 gangliosidosis patient urine samples compared to normal controls.
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To carry this out we used GRIL-LC/MS in which urinary KS was first
digested with keratinase II and then labeled with [12C6]aniline. The
cumulative ion intensity for all KS digestion products for each sample
was compared to one of the normal controls used as a reference sample
that had been heavy isotope labeled with [13C6]aniline. This approach
allowed us to measure relative differences in KS levels among the
affected and unaffected normal controls. We chose as our reference the
control sample with the highest KS levels among the six normal controls
(dotted line in Fig. 10C). Only three of the patient samples had urinary
KS levels significantly elevated above this level while the other three
affected samples exhibited KS levels at or below this level (Fig. 10C).
The patient with the highest urinary A2G2’ levels also exhibited the
Fig. 8. Ganglioside and BMP-phospholipid levels in normal human and GM1 gangliosidosis patient brain homogenates. A. Ganglioside levels in human brain
homogenates including a single GLB1 deficient human and two normal controls. Each ganglioside is normalized to μg protein equivalents. B. BMP-phospholipid levels
normalized to mg protein equivalents.
Fig. 9. Glycan metabolites in a human GM1 gangliosidosis patient brain homogenate. A. Soluble glycan metabolites in brain homogenates were analyzed by LC/MS
and data-dependent MS/MS as previously described. Different size oligosaccharides are symbolically indicated with putative structures based on m/z values,
available CID spectra, and retention times. The m/z values for each oligosaccharides are also shown. The upper panel shows the glycan metabolites in the GLB1
deficient patient while the results for one of the normal controls is shown in the bottom panel (both controls gave the same negative results for glycan metabolites).
The star in the bottom panel denotes a species with m/z value that does not correspond to a glycan and is likely a contaminant. B. Quantitation of the A2G2’
metabolite is shown for all three brain homogenates normalized to mg protein equivalents.
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highest urinary KS levels. These results suggest that in some patients
both N-glycan and KS metabolites are elevated and in other patients just
N-glycans levels are increased while KS levels are not significantly af-
fected. Neither CSF nor brain tissue samples were available from the six
GM1 gangliosidosis patients so we were not able to evaluate ganglioside
accumulation to compare to both A2G2’ and KS levels. Despite this, our
results demonstrate that glycan metabolite levels such as those for the
N-glycan metabolite A2G2’ correlate well with disease and may be as
good a biomarker for GM1 gangliosidosis as GM1 gangliosides. Given
the ease of obtaining urine samples from patients, measuring urinary
glycan metabolite levels may be a more clinically relevant means of
biochemically assessing disease.
4. Discussion
In this study we carried out a comprehensive survey of β-galacto-
sidase substrates that accumulate in GM1 gangliosidosis by probing a
related mouse model for this disease. This allowed us to develop a
quantitative set of assays that assess multiple biomarkers impacted by
loss of GLB1 enzyme activity and give a more complete picture of dis-
ease severity and a wider-ranging panel of endpoints with which to
evaluate the efficacy of new therapeutics to treat this disease. This
panel of biomarkers include a set of gangliosides and soluble glycan
metabolites, each one of which contain terminal non-reducing end β-
linked galactose, which is the definitive substrate for GLB1 found in a
number of glycoconjugates. In addition to these primary biomarkers,
we also evaluated the steady state levels of BMP(22:6) phospholipid, a
secondary biomarker previously shown to be effected in gangliosidoses
such as GM1 gangliosidosis [30].
In order to develop an efficient LC/MS/MS assay for gangliosides, it
was necessary to determine which isoforms to measure. We used
tandem mass spectrometry to determine the predominant acyl-isoforms
of GM1 present in both GLB1−/− and wild type mice and found that
just two isoforms, GM1(d18:1/18:0) and GM1(d18:1/20:0), con-
tributed to almost all of the total ion intensity for this class of glycolipid
in brain. This was found to be true in both murine and human samples.
We therefore developed an LC/MS/MS assay to quantify just these two
acyl-isoforms in biological samples to assess ganglioside steady state
levels. For measuring soluble glycans, we developed a quantitative
assay for one member of this type of molecule, A2G2’, after establishing
that most if not all glycan metabolites as well as ganglioside and BMP
(22:6) levels are similarly effected by GLB1 deficiency. Thus, quanti-
tation of A2G2’ holds the promise of being an effective readout for
GLB1 deficiency in tissues and more easily obtainable biological fluids
such as urine where little to no gangliosides can be detected.
Because a number of different glycoconjugates might serve as sub-
strates for GLB1-dependent degradation, it is important to assess all of
the undegraded substrates that accumulate in GM1 gangliosidosis.
Surveying how different metabolites are effected in different tissues
may lead to a better understanding of what drives disease and how
disease progresses in different organs and tissues. Along those lines,
besides developing comprehensive assays to assess the efficacy for new
therapeutics, another motivation for carrying out this study was to
discover alternative GLB1 substrates that may play important roles in
this disease.
Krabbe disease (OMIM 245200) is a rare autosomal recessive lyso-
somal storage disorder caused by deficiency of galactocerebrosidase
(GALC, EC 3.2.1.46) activity leading to the accumulation of the cere-
broside galactosylceramide. Krabbe is a severe and often fatal neuro-
degenerative disease in children [2]. Like GLB1, GALC, is a β-linked
galactosidase that acts on terminal galactose directly linked to sphin-
golipids. Interestingly, GALC deficiency also leads to the accumulation
of the globoside lactosylceramide consistent with this species also being
a substrate for the GALC enzyme [35,36]. Given that multiple glycoli-
pids accumulate in Krabbe, we wanted to assess if a similar pattern
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search of alternative glycolipid substrates that like GM1 and GA1
gangliosides are also effected by GLB1 deficiency and might play a role
in disease progression. Our lipidomics screen only detected in the
GLB1−/− mouse the accumulation of GM1, GA1, and BMP(22:6). We
did not detect significant increases in lactosylceramide, galactosylcer-
amide, sulfatides, or monogalactosyldiacylglycerol levels in the GLB1
Fig. 10. Urinary A2G2’ and keratan sulfate levels compared between human GM1 gangliosidosis patients and normal unaffected controls. Urine from six normal
pediatric subjects (NHU) and from 6 affected patients diagnosed with infantile GM1 gangliosidosis (P) were analyzed for urinary A2G2’ and KS. A. Representative
results showing the extracted ion current for soluble glycan metabolites in urine from an affected pediatric patient, P09–1212, (top trace) and a normal pediatric
control, NHU4499, (bottom trace). Putative structures for the glycans are shown along with their m/z values and corresponding oligosaccharide sizes (dp). All six
affected patients showed similar results. The normal control exhibited only trace amounts of dp5 and dp6 oligosaccharides as well as the added A2G2’ internal
standard (IS). All of the normal pediatric controls exhibited similar results. B. Urinary A2G2’ levels in six normal pediatric and six GM1 gangliosidosis pediatric
patient urine samples normalized to creatinine levels. C. Keratinase II digestion products were labeled with [12C6]aniline and mixed with keratinase II digestion
products from one of the normal controls (NHU4499) differentially isotope labeled with [13C6]aniline. Ion abundances for KS digestion products were summed
together and the aggregate results normalized to creatinine levels. The fold increase in the cumulative abundances was determined ratiometrically against those of
the spiked heavy isotope control reference. One-fold increase is denoted by the dotted line.
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null mouse, consistent with these galactosyl-lipids being substrates for
other β-linked galactosidases and not for GLB1.
In comparing the relative increases we observed between sialidated
GM1 and asialo GA1 gangliosides, the greatest level of increase was for
GA1 species. In the unaffected normal sample, GA1 levels were at or
near negligible levels, suggesting that much of the GA1 we see accu-
mulating in affected samples results from secondary storage. This is
consistent with a model for lessening of the GM1 burden in affected
cells by conversion of GM1 to GA1 by the action of lysosomal sialidase
activity. We saw this pattern in both murine and human samples de-
monstrating its importance across different species.
In addition to glycolipids, a number of previous studies have de-
monstrated the significant accumulation of soluble (free) glycan me-
tabolites in various gangliosidoses including GM1 gangliosidosis
[3–16,19,37]. These results suggest that GM1 gangliosidosis might be
more accurately described as an oligosaccharidosis which effects the
degradation of multiple glycoconjugates including gangliosides and
glycoproteins. The vast majority of these previously characterized dis-
ease-related soluble glycans were found to be metabolites derived from
incompletely degraded N-linked glycans such as A1G1, A2G2, A3G3,
and A4G4. We analyzed the soluble fraction of tissue homogenates and
urine samples and observed many of these same N-glycan metabolites
from affected mice and humans. However, little or no signs of these
species were detected in unaffected controls demonstrating the corre-
lation with disease exhibited by these metabolites. Many of the previous
studies showing the existence of these soluble glycans were limited by
the use of either liquid chromatography without mass spectrometry or
direct infusion methods such as MALDI and ESI which cannot distin-
guish between isobaric species. Using a more comprehensive method of
glycan analysis, GRIL-LC/MS and data-dependent CID, we were able to
isolate and structurally elucidate a variety of different isobaric species
that included both N-linked and O-linked glycan metabolites. We de-
tected a number of different isobaric series including series for dp5,
dp6, dp7, dp8, and larger oligosaccharides. Of particular interest is a
pentasaccharide series that had the general structure Hex3HexNAc2 and
contributed to a large part of the total ion intensity for glycan meta-
bolites in affected samples. We detected at least nine of these penta-
saccharide isobaric species with the structure Hex3HexNAc2 (m/z value
of 988.4). Most of these dp5 isobars exhibited product ion profiles
consistent with mucin type extended core 1 or 2 O-linked glycans.
These species have not been previously described. In fact, only a few O-
linked glycan metabolites have been previously observed and these
were no larger than a tetrasaccharide. The large contribution to the
total ion intensity by the dp5 glycan metabolites we detected suggests
that they may play an important role in this disease. These species were
detected in multiple tissue and urine taken from GLB1 null mice and
affected human patients with the only difference being differences in
the relative ion intensity between unique dp5 isobars. Since it was
outside the scope of this study, we did not attempt to structurally elu-
cidate these species any further. It will be important for future studies
to do a more complete structural determination of these isobars to help
determine their importance in different tissues and longitudinally in
afflicted patients. Their structural elucidation may also facilitate the
synthesis of standards for their quantification by LC/MS methods.
The N-glycan metabolite A2G2’ was chosen as a surrogate glycan
biomarker because its levels are affected by GLB1 deficiency similarly
to those of other glycan metabolites. Furthermore, it was possible to
generate the corresponding standard by enzymatic removal of the re-
ducing end GlcNAc from its precursor oligosaccharide in defined
amounts suitable for quantitation by GRIL-LC/MS. In addition to its use
as an internal standard for quantitation, the A2G2’ standard allowed us
to determine which of the isobaric dp8 species was in fact A2G2’ by it
relative retention time and product ion profile. Thus, A2G2’ is the only
glycan metabolite that accumulates in disease that we have a complete
structural determination for.
In total, 56 different glycan structures were detected in mouse brain
and many of these were also detected in a number of different tissues
and biological fluids taken from GLB1 null mice showing that the en-
zymatic deficiency effects this class of substrate throughout the animal
and not just in the CNS. The major differences we noticed involved the
relative proportions of the various glycan metabolites and isoforms
from tissue to tissue. For example, A2G2’ levels were proportionately
very low in brain and much higher in peripheral tissues and in urine.
However, O-linked pentasaccharide levels were highest in the brain. All
of the tissues as well as urine exhibited high levels of soluble glycans in
affected mice. In contrast, plasma glycan metabolite levels were very
low with only a few of the glycans seen in tissues and urine detected
suggesting that these metabolites are cleared rapidly from the circula-
tion.
While GRIL-LC/MS combined with data-dependent MS/MS to detect
and structurally characterize soluble glycan metabolites is a more
comprehensive approach for analyzing soluble glycans, it does have its
limitations. It worked best with smaller more abundant oligosacchar-
ides especially dp5 and dp6 isobars for which abundant product ions
that include the aniline labeled reducing end are produced. Inter-ring
cleavages resulting in neutral loss product ions gave insight into how
the monosaccharide units that make up the parent species are arranged
relative to the labeled reducing end. In addition, product ions formation
was informative regarding what NRE residues are present. Thus it was
possible to detect O-linked glycan metabolites and distinguish them
from N-linked glycans. This approach, however, became less effective
with larger oligosaccharides either because ion abundances were less
for these larger species or because the only product ions observed were
generated by the neutral loss of disaccharides and larger subunits. For
example, the loss of a 365 Da subunit could be either a HexHexNAc or a
HexNAcHex disaccharide. In the case of these larger species, we made
no attempts to improve the quality of the data by injecting larger
amounts or attempting to purify specific glycans since many were at
lower relative abundance. For those isobaric species with higher
abundances and more complete product ion formation, two structural
signatures were important in determining oligosaccharide structure.
The first was the existence of product ions with m/z value consistent
with a trihexose directly linked to aniline tagged HexNAc at the redu-
cing end of the molecule. The reducing end product ion Hex2HexNAc is
consistent with both the Man2GlcNAc core structure of N-linked glycans
as well as a Gal2GalNAc sequence found in some O-linked glycans. The
second important feature is the generation of two primary product ions,
one generated by the neutral loss of a single Hex (presumably ga-
lactose) and the other generated by the loss of a single HexNAc. This
profile is consistent with mucin type extended Core 1 and 2 O-linked
glycans.
Mutations in the GLB1 gene effecting β-galactosidase expression and
activity lead to the development of two clinically distinct diseases. GM1
gangliosidosis, which is characterized by the accumulation of GM1,
exhibits severe neurological symptoms. On the other hand, Morquio B
(MPS IVB) results in the accumulation of keratan sulfate and is largely a
skeletal disorder not associated with neuropathology [2,20,34]. In cases
where GM1 gangliosidosis patients were tested, only modest increases
in KS was detected compared to the very high levels seen in Morquio B
patients. In addition, Morquio B patients don't appear to accumulate
large amounts of gangliosides. Attempts to reconcile this paradox have
centered on the notion that different sets of mutations within the GLB1
gene can effect different sets of β-galactosidase substrates thus leading
to the development of different clinical outcomes [34].
While same-patient human brain and urine samples were not
available for this study, our results for urinary KS levels in human pa-
tients showed only modest increases in KS steady state levels in just a
few of the patients tested. However, glycan metabolite levels as mea-
sured by A2G2’, which appear to correlate well with ganglioside levels,
where dramatically increased in all patients. Urinary KS levels were
significant in age-matched normal controls and had levels at or higher
than those detected in half of the affected patients. However, A2G2’
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levels were below the limit of detection in all normal controls. These
observations are consistent with the preferential-substrate model sug-
gesting different types of GLB1 mutations effecting distinct sets of
substrates. Unfortunately, Morquio B patient samples were not avail-
able for this study so we were not able to determine if glycan meta-
bolites increase in this lysosomal disorder as well or if they are specific
for GM1 gangliosidosis. It will be interesting to analyze Morquio B
patients for increases in glycan metabolites in order to better under-
stand how different mutations can lead to different clinical outcomes
and what factors contribute to those clinical fates.
The role played by oligosaccharide metabolites in GM1 gang-
liosidosis is not well understood but is likely to be significant. While we
found more ganglioside accumulation in the GLB1 null brain than the
sum total of all soluble glycans, the accumulation of glycan metabolites
in peripheral tissues, where ganglioside levels are normally low com-
pared to the CNS, should be an important feature of this disease. Thus
aspects of the disease outside of the CNS, such as hepatosplenomegaly
and skeletal abnormalities, may be driven to some degree by glycans
and not gangliosides. However, the accumulation of glycans in the CNS
may be, along with ganglioside accumulation, also an important driver
in the neuropathology of the disease. Consistent with this idea is the
role played by soluble glycan accumulation in a related oligosacchar-
idosis disorder α-mannosidosis which is caused by a deficiency of α-
mannosidase [38]. This disorder exhibits similar clinical symptoms to
those of GM1 gangliosidosis including severe neurological deteriora-
tion. Interestingly, α-mannosidosis does not lead to the accumulation of
gangliosides but instead only mannose-containing oligosaccharide me-
tabolites which accumulate in the lysosomes of affected cells (see
Fig. 1). Furthermore, since α-mannosidase deficiency effects pre-
dominantly N-linked glycans, the total amount of glycans accumulating
in α-mannosidosis should be significantly lower than what is observed
in GM1 gangliosidosis since the latter disease effects both N-linked and
O-linked glycan metabolites both of which, we observed, show sig-
nificant accumulation. The similar symptoms suffered by both GM1
gangliosidosis and α-mannosidosis patients suggests that the lysosomal
accumulation of glycan metabolites can play an important role in the
development of symptoms in both disorders and that gangliosides may
not be the sole driver of pathology in GM1 gangliosidosis.
By monitoring different classes of accumulating GLB1 substrates, we
are better equipped to evaluate multiple aspects of GM1 gangliosidosis.
While many of the N-linked glycan metabolites we detected were ob-
served in previous studies, our discovery of a number of N-glycan iso-
baric species as well as a number of new O-linked glycans adds a new
dimension to our understanding of this disease. Importantly, we found
that the steady state levels of these soluble glycan metabolites correlate
well with those of gangliosides in this disease, potentially making them
good surrogate biomarkers especially when considering their detection
in an easily obtainable sample matrix such as urine. Measuring urinary
levels of these glycans should make longitudinal studies and measuring
the efficacy of new therapeutics much easier by eliminating the need for
invasive analytical procedures. Furthermore, given the paucity of GM1
gangliosides in urine, urinary oligosaccharides such as A2G2’ are at-
tractive candidates for second tier biomarkers to confirm β-galactosi-
dase activity measurements as part of newborn screening once suc-
cessful therapies become available. Further work to validate these
finding in a larger set of patients will be required to firmly establish the
usefulness of measuring these metabolites for routine clinical analysis.
5. Conclusion
We carried out a comprehensive survey of β-galactosidase substrates
that accumulate in a mouse model for GM1 gangliosidosis. These sub-
strates include both gangliosides and soluble glycan metabolites which
all have in common the definitive substrate for GLB1, β-linked ga-
lactose at their non-reducing ends. In addition to detecting N-glycan
metabolites known to accumulate in this disorder, we discovered a
number of species not previously described including species whose
product ion spectra are consistent with metabolites derived from O-
glycans. Many of these disease-related metabolites were also detected
in affected human samples at significant levels. We developed a set of
quantitative assays that assess multiple biomarkers impacted in this
genetic disorder giving a more complete picture of disease severity and
a larger panel of endpoints with which to evaluate the efficacy of new
therapeutics.
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